Participants with symptomatic SARS-CoV-2 infection
SARS-COV-2 INFECTION
The analyses of SARS-CoV-2 infection in this manuscript are restricted to participants in the fully vaccinated analysis set (FVS) (i.e., those who were SARS-CoV-2 seronegative at baseline and remained on the study for ≥15 days after their second dose of primary series AZD1222 or placebo without SARS-CoV-2 infection) who experienced their first symptomatic RT-PCR-confirmed SARS-CoV-2 infection and provided samples during the 28-day illness period. The overall number of FVS participants who initiated illness visits and had confirmed SARS-CoV-2 positive symptomatic illness confirmed by adjudication was low (AZD1222: 